Arcus Biosciences Shares Drop 12% After Discontinuing Phase 3 STAR-221 Trial
Arcus BiosciencesArcus Biosciences(US:RCUS) RTTNews·2025-12-13 01:57

Arcus Biosciences, Inc. (RCUS) is trading 11.50 percent lower at 22.25,down22.25, down 2.89 on Friday, after announcing the discontinuation of its Phase 3 STAR-221 study conducted with Gilead Sciences. The stock opened at 21.15andhastradedbetween21.15 and has traded between 20.35 and 24.00sofarontheNewYorkStockExchange.Thebidsitsat24.00 so far on the New York Stock Exchange. The bid sits at 22.54 and the ask at 22.60,withvolumeat4,426,823versusanaverageof1,561,846.Arcussharesarenowtradingwellofftheirrecentpeak,withina52−weekrangeof22.60, with volume at 4,426,823 versus an average of 1,561,846.Arcus shares are now trading well off their recent peak, within a 52-week range of 6.50 to $26.40. For comm ...